Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies

Broadly neutralizing antibodies are showing promise in the treatment and prevention of HIV-1, with several now being evaluated clinically. Some lead clinical candidates, including antibodies CAP256-VRC26.25, N6, PGT121, and VRC07-523, have one or more N-linked glycosylation sequons in their variable...

Descripción completa

Detalles Bibliográficos
Autores principales: Chuang, Gwo-Yu, Asokan, Mangaiarkarasi, Ivleva, Vera B., Pegu, Amarendra, Yang, Eun Sung, Zhang, Baoshan, Chaudhuri, Rajoshi, Geng, Hui, Lin, Bob C., Louder, Mark K., McKee, Krisha, O’Dell, Sijy, Wang, Hairong, Zhou, Tongqing, Doria-Rose, Nicole A., Kueltzo, Lisa A., Lei, Q. Paula, Mascola, John R., Kwong, Peter D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643989/
https://www.ncbi.nlm.nih.gov/pubmed/33121334
http://dx.doi.org/10.1080/19420862.2020.1836719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643989/
https://www.ncbi.nlm.nih.gov/pubmed/33121334
http://dx.doi.org/10.1080/19420862.2020.1836719

Ejemplares similares